Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy | Zendy

Gregory P. Hess | Zendy; Pradeep Natarajan | Zendy; Kamil F. Faridi | Zendy; Anna Fievitz | Zendy; Linda R. Valsdottir | Zendy; Robert W. Yeh | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy

Author(s) -

Gregory P. Hess,

Pradeep Natarajan,

Kamil F. Faridi,

Anna Fievitz,

Linda R. Valsdottir,

Robert W. Yeh

Publication year - 2017

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.117.028430

Subject(s) - kexin , proprotein convertase , subtilisin , medicine , pcsk9 , pharmacology , cholesterol , biochemistry , ldl receptor , lipoprotein , enzyme , chemistry

Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) are a novel class of medications for patients with familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease requiring additional lipid lowering beyond dietary measures and statin use. Because of the drugs' high cost, rates of prescription approval by payers may be low. We aimed to identify payer approval and rejection rates for PCSK9i prescriptions and the potential factors influencing these rates.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research